Aethlon Medical (NASDAQ:AEMD) Stock Price Passes Below 200-Day Moving Average – What’s Next?

Aethlon Medical, Inc. (NASDAQ:AEMD) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $6.80 and traded as low as $2.30. Aethlon Medical shares last traded at $2.33, with a volume of 31,465 shares traded.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research report on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $560.00.

Aethlon Medical Stock Performance

The company has a 50 day moving average of $3.04 and a two-hundred day moving average of $6.80. The stock has a market capitalization of $2.26 million, a PE ratio of -0.10 and a beta of 1.60.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Wednesday, November 12th. The medical equipment provider reported ($3.74) earnings per share for the quarter, missing the consensus estimate of ($1.70) by ($2.04). As a group, research analysts predict that Aethlon Medical, Inc. will post -0.73 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC acquired a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent SEC filing. 1.99% of the stock is owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.